References

Osteoblast function in patients with idiopathic osteonecrosis of the femoral head

10.1302/2046-3758.109.bjr-2021-0016.r1 · 2021 · External reference

Risk factors for revision of primary total hip arthroplasty: a systematic review

10.1186/1471-2474-13-251 · 2012 · External reference

Natural history and conservative treatment of osteonecrosis (ON) of the femoral head

10.1177/112070009800800209 · 1998 · External reference

Risk factors for early revision after total hip and knee arthroplasty: national observational study from a surgeon and population perspective

10.1371/journal.pone.0214855 · 2019 · External reference

Zoledronic acid improves femoral head sphericity in a rat model of perthes disease

10.1016/j.orthres.2004.11.015 · 2005 · External reference

Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents

10.2106/00004623-200708000-00009 · 2007 · External reference

RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis

10.1359/jbmr.060905 · 2006 · External reference

Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg–Calve–Perthes disease

10.1016/j.bone.2009.04.255 · 2009 · External reference

Use of zoledronic acid for treatment of chemotherapy related osteonecrosis in children and adolescents: a retrospective analysis

10.1002/pbc.24563 · 2013 · External reference

The efficacy of Denosumab in the treatment of femoral head osteonecrosis: a retrospective comparative study

10.1038/s41598-024-54685-7 · 2024 · External reference

Denosumab can prevent collapse in patients with early-stage steroid-induced osteonecrosis of the femoral head by inhibiting osteoclasts and autophagy

10.1111/os.13584 · 2023 · External reference

Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI

2018 · External reference

Hypercalcemia following discontinuation of denosumab therapy: a systematic review

2021 · External reference

Childhood type 1 diabetes is associated with abnormal bone development

10.1111/pedi.13367 · 2022 · External reference

Expression of osteoprotegerin, RNAK and RANKL genes in femoral head avascular necrosis and related signaling pathway

2015 · External reference

Treatment of pre-collapse stages of osteonecrosis of the femoral head: a systematic review of randomized control trials

10.1007/s11420-016-9505-9 · 2016 · External reference

Denosumab and surgery for the treatment of Perthes’ disease in a 9-year-old boy: favorable course documented by comprehensive imaging— a case report

10.1080/17453674.2017.1298020 · 2017 · External reference

Denosumab-induced rebound hypercalcemia treated with bisphosphonates in a pediatric patient

2023 · External reference

Denosumab discontinuation and the rebound phenomenon: a narrative review

10.3390/jcm10010152 · 2021 · External reference

Efficacy and safety of denosumab therapy for osteogenesis imperfecta patients with osteoporosis—case series

10.3390/jcm7120479 · 2018 · External reference

Safety and efficacy of denosumab in children with osteogenesis imperfect—a first prospective trial

2016 · External reference

Safety and efficacy of denosumab in children with osteogenesis imperfecta—the first prospective comparative study

10.1210/clinem/dgad732 · 2024 · External reference

Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review

10.21037/tp-22-276 · 2023 · External reference

Effect of denosumab on the growing skeleton in osteogenesis imperfecta

10.1210/jc.2014-3072 · 2014 · External reference

Dense sclerotic metaphyseal bands caused by denosumab therapy

10.1007/s00247-020-04651-y · 2020 · External reference

Zoledronic acid in pediatric metabolic bone disorders

10.21037/tp.2017.09.10 · 2017 · External reference

Acute phase response and mineral status following low dose intravenous zoledronic acid in children

10.1016/j.bone.2007.05.002 · 2007 · External reference